<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03476668</url>
  </required_header>
  <id_info>
    <org_study_id>MIRT-RTs-Laterality</org_study_id>
    <nct_id>NCT03476668</nct_id>
  </id_info>
  <brief_title>Relationship Between Dopaminergic Asymmetric Degeneration and Attentional Resources in Parkinson's Disease.</brief_title>
  <acronym>RTsAsMIRT</acronym>
  <official_title>Relationship Between Dopaminergic Asymmetric Degeneration and Attentional Resources in Parkinson's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Generale Di Zona Moriggia-Pelascini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Generale Di Zona Moriggia-Pelascini</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers aimed to investigate the relationship between the asymmetric dopaminergic
      degeneration and the attentional resources in a group of patients with Parkinson's disease
      (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To bypass the impaired habitual motor-behavioural control, Parkinson's disease (PD) patients
      may exploit the network of goal-directed mode of action. The frontostriatal connections
      underline this functioning, that is based on attention. Since the cognitive processes are
      related with dopamine, the asymmetrical degeneration of the dopaminergic system affects
      differently the right side affected (RPD) and the left side affected (LPD) PD patients.

      The aim of the study was to investigate the relationship between the asymmetric dopaminergic
      degeneration and the attentional resources in a group of patients with PD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">May 1, 2016</completion_date>
  <primary_completion_date type="Actual">May 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Reaction Times (V RTs)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Visual Reaction Times</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Auditory Reaction Times (A RTs)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Auditory Reaction Times</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Choices RTs (MC RTs)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Multiple Choices RTs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Unified Parkinson's Disease Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed Up and Go Test (TUG)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Timed Up and Go Test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Attention Disturbances</condition>
  <arm_group>
    <arm_group_label>RPD PD patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Right-side affected PD patients. Intervention: MIRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPD PD patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Left-side affected (LPD) PD patients. Intervention: MIRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MIRT</intervention_name>
    <description>4-week multidisciplinary intensive rehabilitation treatment</description>
    <arm_group_label>RPD PD patients</arm_group_label>
    <arm_group_label>LPD PD patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage 2.5-3 according to the Hoehn and Yahr scale (H&amp;Y);

          -  Stable pharmacological treatment for the last 6 weeks before the enrolment and during
             the hospitalization;

          -  Mini Mental State Examination (MMSE) â‰¥ 24;

          -  No evidences of dysexecutive syndrome.

        Exclusion Criteria:

          -  Any focal brain lesion detected in brain imaging studies (CT or MRI) performed in the
             previous 12 months;

          -  Drug-induced dyskinesias;

          -  Disturbing resting and/or action tremor, corresponding to scores 2-4 in the specific
             items of UPDRS III;

          -  Behavioral disturbances (evaluated with Neuropsychiatric Inventory);

          -  Visual and auditory dysfunctions according to the general clinical evaluation and
             medical history;

          -  Equivocal report about the side of disease onset or bilateral motor involvement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Frazzitta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>epartment of Parkinson's disease, Movement Disorders and Brain Injury Rehabilitation, &quot;Moriggia-Pelascini&quot; Hospital - Via Pelascini, 3, 22015, Gravedona ed Uniti, Como, Italy</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2018</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

